title: A comparison of regular with intermittent bronchodilators in asthma patients on inhaled steroids.
abstract: The aim of this study was to compare the effect of regular versus intermittent (p.r.n.) bronchodilators on bronchial reactivity and asthma control in patients on concomitant inhaled corticosteroids. We studied 12 patients with asthma in a prospective, randomised, single-blind, single-dummy, three-period crossover trial comparing placebo (2 puffs t.d.s.), salbutamol (200 micrograms t.d.s.) and oxitropium bromide (200 micrograms t.d.s.) for 28 days each. Computerised spirometry and bronchial reactivity to histamine were obtained on entry and after each treatment period. Symptom scores, use of rescue bronchodilator and peak expiratory flow rates were recorded daily. There were no significant differences in bronchial hyperreactivity between the salbutamol, oxitropium and placebo treatment periods. There were no significant differences in baseline FEV1, FEF25-75%, symptom scores, use of rescue bronchodilator or morning and evening PEFR between treatment periods. Intermittent beta agonist therapy is as effective as regular therapy in terms of asthma control and bronchial hyperreactivity in patients on concomitant inhaled corticosteroid therapy. Since intermittent therapy achieves similar results with significantly lower beta agonist consumption, the data support current recommendations that beta agonists should be taken on a p.r.n. basis in asthma patients on inhaled steroids.
authors.affiliation: Department of Respiratory Medicine, James Connolly Memorial Hospital, Blanchardstown, Dublin.
authors.forename: V J
authors.initials: VJ
authors.lastname: Tormey
authors.forename: J
authors.initials: J
authors.lastname: Faul
authors.forename: C
authors.initials: C
authors.lastname: Leonard
authors.forename: A
authors.initials: A
authors.lastname: Lennon
authors.forename: C M
authors.initials: CM
authors.lastname: Burke
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D000420:Albuterol / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy*; D001507:Beclomethasone / Q000008:administration & dosage*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy*; D001985:Bronchial Provocation Tests; D001993:Bronchodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012602:Scopolamine Derivatives / Q000008:administration & dosage* / Q000009:adverse effects; D016037:Single-Blind Method
chemical_list: D001993:Bronchodilator Agents; D005938:Glucocorticoids; D010276:Parasympatholytics; D012602:Scopolamine Derivatives; C017590:oxitropium; D001507:Beclomethasone; D000420:Albuterol